CIK 0001157601
- Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 267-824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- 4 Open-market buy Director bought 500,000 shares at an average $4.53 ($2,265,390)
- 4 Open-market buy Director bought 250,000 shares at an average $4.39 ($1,097,440)
- 4 Open-market buy President and CEO bought 20,000 shares at $4.12 ($82,374)
- 4 Open-market buy Director bought 200,000 shares at $4.00 ($799,160)
- 4 Open-market buy President and CEO bought 10,000 shares at $4.06 ($40,550)
- 4 Open-market buy President and CEO bought 10,000 shares at $4.04 ($40,390)
- 4 Open-market buy Director bought 2,000,000 shares at an average $4.64 ($9,270,354)
- 4 Open-market buy SVP, Chief Medical Officer bought 10,000 shares at $4.58 ($45,800)
- 4 Open-market buy Director bought 10,000 shares at $5.00 ($50,000)
- 4 Grant or award President, R&D acquired 75,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 5 Insider Annual Insider Trading Report
- 5 Insider Annual Insider Trading Report
- 4 Option exercise Director acquired 114,250 shares (option exercise)
- 4 Grant or award Director acquired 58,140 shares (grant or award)
Page 19 of 29 · 564 filings